These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 17722954)

  • 1. Metastatic colorectal cancer: current systemic treatment options.
    Board RE; Valle JW
    Drugs; 2007; 67(13):1851-67. PubMed ID: 17722954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer.
    Larsen FO; Pfeiffer P; Nielsen D; Skougaard K; Qvortrup C; Vistisen K; Fromm AL; Jørgensen TL; Bjerregaard JK; Hoegdall E; Jensen BV
    Acta Oncol; 2011 May; 50(4):574-7. PubMed ID: 21529301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer.
    Hurwitz H
    Clin Colorectal Cancer; 2004 Oct; 4 Suppl 2():S62-8. PubMed ID: 15479481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New systemic frontline treatment for metastatic colorectal carcinoma.
    Braun AH; Achterrath W; Wilke H; Vanhoefer U; Harstrick A; Preusser P
    Cancer; 2004 Apr; 100(8):1558-77. PubMed ID: 15073842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters.
    Ku GY; Haaland BA; de Lima Lopes G
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):231-8. PubMed ID: 22699811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Recent results of irinotecan therapy in colorectal cancer].
    Láng I; Hitre E
    Magy Onkol; 2004; 48(4):281-8. PubMed ID: 15655572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on clinical data combining capecitabine with targeted agents in newly diagnosed colorectal cancer.
    Lee JJ; Chu E
    Clin Colorectal Cancer; 2007 Dec; 7 Suppl 1():S16-20. PubMed ID: 18361802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
    Tappenden P; Jones R; Paisley S; Carroll C
    Health Technol Assess; 2007 Mar; 11(12):1-128, iii-iv. PubMed ID: 17346499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
    Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
    Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integration of novel agents in the treatment of colorectal cancer.
    Iqbal S; Lenz HJ
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current status of second-line therapy for metastatic colorectal cancer.
    Rothenberg ML
    Clin Colorectal Cancer; 2004 Jun; 4 Suppl 1():S16-21. PubMed ID: 15212701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Seeing the forest through the trees: a systematic review of the safety and efficacy of combination chemotherapies used in the treatment of metastatic colorectal cancer.
    Bekaii-Saab T; Wu C
    Crit Rev Oncol Hematol; 2014 Jul; 91(1):9-34. PubMed ID: 24534706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The addition of bevacizumab to fluoropyrimidine, irinotecan and oxaliplatin-based therapy improves survival for patients with metastatic colorectal cancer (CRC): combined analysis of efficacy.
    Popov I; Milicević M; Radosević-Jelić Lj
    Acta Chir Iugosl; 2008; 55(4):11-6. PubMed ID: 19245134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual Inhibition of EGFR and VEGF in Heavily Pretreated Patients with Metastatic Colorectal Cancer.
    Larsen FO; Markussen A; Nielsen D; Colville-Ebeling B; Riis LB; Jensen BV
    Oncology; 2017; 93(3):191-196. PubMed ID: 28531891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New developments in systemic chemotherapy in advanced colorectal cancer.
    Cats A
    Scand J Gastroenterol Suppl; 2003; (239):78-86. PubMed ID: 14743888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Critical evaluation of current treatments in metastatic colorectal cancer.
    Venook A
    Oncologist; 2005 Apr; 10(4):250-61. PubMed ID: 15821245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New oxaliplatin-based combinations in the treatment of colorectal cancer.
    Cassidy J; Hochster H
    Colorectal Dis; 2003 Nov; 5 Suppl 3():1-9. PubMed ID: 23573555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second-line treatment of patients with metastatic colorectal cancer.
    Rougier P; Lepere C
    Semin Oncol; 2005 Dec; 32(6 Suppl 9):S48-54. PubMed ID: 16399432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer.
    Köhne CH; Lenz HJ
    Oncologist; 2009 May; 14(5):478-88. PubMed ID: 19411318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.